AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia.
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Addex Therapeutics (ADXN – Research Report), ...
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
One of the first no-brainer dividend stocks to buy with $100 right now is AT&T. At recent prices, America's second-largest telecommunications business by revenue offers a juicy 5.1% dividend yield.
Hosted on MSN2d
US FDA approves new schizophrenia drugThe US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback